The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have
With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is
At Anteris we bring
The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.
The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to
At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.
Annual General Meetings
Computershare Investor Services Pty Ltd
Level 1, 200 Mary Street
Brisbane, QLD 4000
T 1300 850 505 (within Australia)
T +61 3 9415 4000 (outside Australia)
F 1800 783 447 (within Australia)
F +61 3 9473 2555 (outside Australia)
ComputerShare Investor Services manages our share registry. You can contact them for details about your holding here.
A copy of our recent top 20 shareholder list is available here.
Holders of Unlisted Options
Conversion Notice and Payment
If you hold unlisted options and wish to exercise those options to convert them into ordinary shares of Anteris Technologies Ltd, you will need to complete an exercise form and submit payment within the period prior to expiry, please contact us at email@example.com and we will be able to provide you with the exercise form which includes details of how to submit payment.
If you have any questions in relation to any of the above, please contact Computershare Investor Services Pty Limited on +61 1300 850 505 or the Company on +61 1300 550 310 or firstname.lastname@example.org.